Bristol Offloads HIV Pipeline To ViiV As It Tightens Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal brings GSK/Pfizer HIV-focused affiliate two novel mechanisms, one of which could be used in combination with Tivicay and another that addresses a different stage of the virus' lifecycle than any HIV drug now approved.